Sept 19 (Reuters) - Vanda Pharmaceuticals Inc :
* FDA DECLINES TO APPROVE VANDA'S MARKETING APPLICATION FOR TRADIPITANT IN GASTROPARESIS
* VANDA PHARMACEUTICALS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO VANDA FOR TRADIPITANT
* VANDA PHARMACEUTICALS INC - FDA SUGGESTS ADDITIONAL STUDIES FOR TRADIPITANT APPROVAL
* VANDA PHARMACEUTICALS INC - TO SUBMIT NDA FOR TRADIPITANT IN MOTION SICKNESS LATER THIS YEAR
* VANDA: BELIEVES TRADIPITANT APPLICATION HAS MET SUBSTANTIAL EVIDENCE OF EFFICACY STANDARD
* VANDA: WILL CONTINUE TO PURSUE MARKETING AUTHORIZATION FOR TRADIPITANT
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.